Of note, monotherapy with active vitamin D or CYP24A1 inhibition alone ameliorate rickets in preclinical mouse models (41, 142, 143) and may reduce the risk of secondary and tertiary hyperparathyroidism, supporting the use of the lowest possible dose of phosphate and higher doses of active vitamin D supplements. Here, CYP24A1 is linked to rickets.